NCT06935552Not yet recruitingEarly phase 1
Ketamine and Lidocaine Infusion in Refractory Chronic Migraine
Ketamine and Lidocaine Infusion for Refractory Chronic Migraine: Comparative Study
Source: ClinicalTrials.gov · Last updated 20 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 7 Apr 2025
- Start date
- Jun 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Migraine
- NCT number
- NCT06935552
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 44
- From Jun 2025 to the primary completion date, Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities
- presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
- patients with hemocoagulation disorders, local infection or those who refused to consent
Other
- participation in any other type of medical research that may interfere with the interpretation of the study.
Who the study is looking for
- All participants must fulfill the following inclusion criteria
- medically stable outpatients with confirmed diagnosis of refractory chronic migraine according to American Headache society
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow up.
- Men or women older than 18years of age.
- clear written informed consent from each participant in the trial.
- Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society
Age in the registry: 18 years to 60 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.